In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CAT Merges for Money; Chooses Well-Dowered OGS

Executive Summary

The merger of Cambridge Antibody Technology and Oxford GlycoSciences won't, in the short term, solve many of the problems that both share--namely, a lack of products, scant clinical development capabilities and a non-existent sales and marketing infrastructure. It does, however, create a financially stronger potential acquiror in a European biotech industry in need of consolidation.
Advertisement

Related Content

CAT Fight with Abbott: The Calculus of Royalty Offsets and Partnering Reputation
Biotechs Beware: Royalty Offset Clauses Can Seriously Damage Your Health
OGS: Going, Going, Gone
The Battle For OGS
Fellner: Celltech's Revenue-Generating Model Key for Biotech
Biotechs on the Brink Choose Last-Minute Deals, Not Liquidation
How Much for That Money in the Window?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel